William Blair Investment Management LLC Purchases 2,172 Shares of Humana Inc. (NYSE:HUM)

William Blair Investment Management LLC increased its stake in Humana Inc. (NYSE:HUM - Free Report) by 13.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,045 shares of the insurance provider's stock after acquiring an additional 2,172 shares during the quarter. William Blair Investment Management LLC's holdings in Humana were worth $4,578,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Pinnacle Wealth Management Advisory Group LLC increased its stake in shares of Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after acquiring an additional 37 shares in the last quarter. Atlas Brown Inc. boosted its holdings in shares of Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after buying an additional 38 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in shares of Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after buying an additional 40 shares during the last quarter. Mather Group LLC. boosted its holdings in shares of Humana by 21.0% in the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after buying an additional 41 shares during the last quarter. Finally, Capital Advisors Ltd. LLC boosted its holdings in shares of Humana by 26.1% in the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after buying an additional 43 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Remove Ads

Humana Trading Down 0.2 %

Shares of NYSE:HUM traded down $0.50 during trading on Friday, reaching $266.33. 1,963,596 shares of the company traded hands, compared to its average volume of 1,714,853. The firm has a market capitalization of $32.14 billion, a price-to-earnings ratio of 26.77, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The business's fifty day moving average is $271.39 and its 200-day moving average is $278.13.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date is Friday, March 28th. Humana's payout ratio is 35.58%.

Analyst Ratings Changes

Several equities research analysts have commented on HUM shares. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Barclays upped their price target on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley decreased their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Humana presently has an average rating of "Hold" and an average price target of $285.68.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.37% of the stock is currently owned by insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.